Navigation Links
Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
Date:2/17/2009

SAN CARLOS, Calif., Feb. 17 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the first patients have been dosed in a Phase 1 dose-escalation study of NKTR-105, a novel PEGylated form of docetaxel. The Phase 1 study will assess the safety, pharmacokinetics and anti-tumor activity of NKTR-105 in approximately 30 patients with refractory solid tumors who have failed all prior available therapies.

"The start of the clinical study for NKTR-105 marks another milestone in the advancement of Nektar's pipeline of innovative therapeutics using our advanced polymer conjugate technology," said Randall Moreadith, M.D., Ph.D., Senior Vice President, Drug Development and Chief Development Officer of Nektar. "NKTR-105 demonstrates a prolonged half-life and tumor exposure as compared to docetaxel. We are excited about the drug's potential to significantly expand therapeutic options for oncologists and patients."

NKTR-105 is a novel form of docetaxel that was developed using Nektar's advanced polymer conjugate technology. Docetaxel is a versatile chemotherapy agent currently approved by the FDA for use in five different cancer indications: breast, non-small cell lung, prostate, gastric and head and neck. Oncolytics such as docetaxel typically have sub-optimal half-lives which can limit their therapeutic efficacy, or have a safety and tolerability profile that limits their use. Nektar's advanced polymer conjugate technology can be used to optimize the bioactivity of these drugs and increase the sustained exposure of active drug to tumor cells in the body.

"Our team at START is extremely pleased to work with Nektar on the first clinical trial of NKTR-105 in cancer patients," said Dr. Anthony Tolcher, Director of Clinical Research at START (South Texas Accelerated Research Therapeutics) and lead
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients
2. Optimal Warfarin Dosing Improves Anticoagulation Control
3. Self-Dosing Pain Medication Errors Too Common: Study
4. Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures
5. Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. Hay fever may be best treated with self-adjusted dosing
8. DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results
9. New Improved Dosing Approved for Pennsaid
10. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
11. Verizon Wireless Customers Can Now Get Medication Information and Dosing Reminders with the Pill Phone Application on Their Phones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 28, 2015 The buyer power score ... of 5, indicating a medium level of buyer power ... suppliers have equal power during negotiations. One factor helping ... purchasing a health insurance policy from an insurance carrier ... buyers can choose to self-fund their own policy or ...
(Date:4/28/2015)... St. Louis, Missouri (PRWEB) April 28, 2015 ... report that delves into the reality problem Americans ... of the population will need long-term care services as ... will need such care. , In the report, ... from organizations such as the American Health Care Association ...
(Date:4/28/2015)... OsteoRemedies®, LLC, Memphis, TN, offers ... of infected hip and knee arthroplasty. ... pre-formed, pre-loaded spacer with Gentamicin Antibiotics, for consistent ... Combined with a consistent process for polishing ... approved for temporary use for up to 180 ...
(Date:4/28/2015)... 2015 Enrollment in programs designed ... 2.2 million in April, according to the editors ... Medicare-Medicaid Dual Eligibles Database , an online subscription ... the dual-eligible community. This is a 14% increase ... initiatives in January, but only covers about a ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 The PracticeMatch ... from 5:00 to 8:00 pm at the Sheraton Colonial Boston ... 50 hospitals, clinics and groups with career opportunities will be ... Attendees will enjoy free hors d’oeuvres and raffle prize drawings. ... says “Boston is an ideal location to hold a ...
Breaking Medicine News(10 mins):Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Enrollment in Duals Programs Increases 14%, New AIS Database Finds 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 3
... REFORM IMPLEMENTATION RECOMMENDS WAYS TO ENSURE ACCESS TO AFFORDABLE ... Full-Year Coverage, Combined Small Business and Individual Health Insurance ... New York, NY, May 19, 2011Modifications to ... and subsidies provided under the Affordable Care Act remain ...
... , WEDNESDAY, May 18 (HealthDay News) -- Long-term ... colon cancers in women with a high risk of breast ... drinking and physical activity affected the risk of several common ... because of family history of breast cancer, age and other ...
... , WEDNESDAY, May 18 (HealthDay News) -- Rep. Gabrielle Giffords, ... assassin, will undergo surgery Wednesday in Houston to replace the ... shooting, according to the Associated Press . This ... days after the three-term Democratic congresswoman from Arizona traveled to ...
... (HealthDay News) -- End-of-life care for older people with advanced ... Canadian province of Ontario, a new study says. U.S. ... much more use of hospital and emergency room services, according ... the Ontario Cancer Registry. The information was collected from people ...
... Rochester Medical Center researchers have pinpointed two genes that ... providing data to support a new investigational treatment that ... Tony Godfrey, Ph.D., a research associate professor of Surgery ... was published by the journal Clinical Cancer Research. ...
... form of childhood cancer acute lymphoblastic leukemia are ... best efforts and the most powerful modern cancer drugs. ... the University of California, San Francisco have uncovered the basis ... use to stay alive. Targeting this protein may be the ...
Cached Medicine News:Health News:New report on health reform implementation: How to ensure access to coverage is maintained 2Health News:New report on health reform implementation: How to ensure access to coverage is maintained 3Health News:Smoking Raises Odds for Cancer in Women Already at High Risk 2Health News:Rep. Giffords to Get Skull Patch in Latest Step in Recovery 2Health News:Rep. Giffords to Get Skull Patch in Latest Step in Recovery 3Health News:End-of-Life Care Differs Between U.S., Canada, Study Finds 2Health News: Researchers home in on genetic signature of esophageal cancer 2Health News: Researchers home in on genetic signature of esophageal cancer 3Health News:UCSF team discovers key to fighting drug-resistant leukemia 2Health News:UCSF team discovers key to fighting drug-resistant leukemia 3
(Date:4/28/2015)... April 28, 2015  Rosa & Co. LLC, a ... and simulation, today announced its pleasure to be lead ... of Quantitative Systems Pharmacology (QSP). The conference focuses on ... ... Rosa,s lead sponsorship is the ...
(Date:4/28/2015)... , April 28, 2015  People with acute coronary ... heart stent are prescribed an oral antiplatelet (OAP) therapy and ... in their heart stent (stent thrombosis), or even death.[3] Yet, ... percent of 275 ACS patients who were currently taking an ... their prescribed OAP therapy, even though most of them were ...
(Date:4/28/2015)... , April 28, 2015 The ... its sixth funding cycle for U.S.- Israel ... Energy Efficiency. To be considered, a project proposal ... a company and a university/research institution (one from the U.S. ... should have significant commercial potential and the project outcome should ...
Breaking Medicine Technology:Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 2Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 4Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 5Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 6Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 7Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 8Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 9Opportunities for Funding U.S.-Israel Cooperation for Renewable Energy and Efficiency 2
... Fla., Jan. 11 Florida Atlantic,University and Scripps ... on Wednesday, January 16 from 4-5:30 p.m. in ... Blobel, M.D., Ph.D.,is the 1999 recipient of the ... D. Rockefeller, Jr. Professor, The Rockefeller University, and,Investigator, ...
... Products Help Address Infection Control, WASHINGTON, Jan. ... hospital operations and minimize risks during times,of health ... that one of its,healthcare products, DuPont(TM) Corian(R) solid ... for its emergency department. The product,recently was incorporated ...
Cached Medicine Technology:Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University 2Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4
... is an in vitro immunoassay intended for the ... associated antigen. It is indicated for use as ... in conjunction with cystoscopy or when prescribed for ... the FDA for prescription home use in February ...
... is a quantitative microplate enzyme immunoassay that detects ... have very small amounts of NMP22 protein in ... is often elevated in the urine of patients ... the disease. The use of the NMP22 protein ...
... Used to connect an ... infusion pump, and then ... in order to conduct ... with Laborie Medical Technologies ...
Used for cystometry and urethral pressure profilometry. A loop is employed to enhance catheter retention and stabilization within the bladder. Supplied sterile in peel-open packages. Intended for one...
Medicine Products: